Issue Date: May 15, 2017
Pfizer gets Sangamo hemophilia treatment
Pfizer has licensed Sangamo Therapeutics’ gene therapy programs for hemophilia A, including SB-525, which is expected to enter the clinic this quarter. Sangamo will get $70 million up front plus milestone payments of up to $300 million. Pfizer is already partnered with Spark Therapeutics on a gene therapy for hemophilia B. Last year Pfizer spent $150 million to acquire Bamboo Therapeutics and its gene therapy manufacturing facility.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society